A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 344 participants.

Also called NCT07285655

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 344 participants (planned count) (from the registry)
Sponsor
Liquidia Technologies, Inc. (from the registry)
Registry
  • NCT NCT07285655
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, France, Germany, Italy, Latvia, Portugal, Spain, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07285655. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-23 (actual); primary completion 2029-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Acronym
Re-Spire
Condition
Pulmonary Hypertension Due to Lung Disease (Disorder)
Intervention (Drug)
L606
Intervention (Drug)
Placebo
Lead sponsor
Liquidia Technologies, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07285655
Content hash
114ab576d39aecdf79e5d050cf38c543c430da4e923ba12660977e0ca4e3133d